LYNN KLIMO: Open Payments
NPI 1184669921 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$521 in 24 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $521
Food & beverage: $521
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $99 |
| Janssen Pharmaceuticals, Inc | 4 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Neurocrine BioSciences, Inc. | 1 | $36 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $25 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: VRAYLAR, REXULTI, FANAPT, INVEGA SUSTENNA, TRINTELLIX, SPRAVATO, CAPLYTA, INGREZZA.
Industry payments across AZ — which companies pay providers there.
